Physician profile
Lawrence E Harrison
NPI 1386733186
$2,045.36
in general payments reported to CMS, 2019-2025
33 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $248 · 2021: $396 · 2022: $338 · 2023: $518 · 2024: $135 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.55 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $233.83 | 2023-2024 | Krazati |
| Novartis Pharmaceuticals Corporation | $211.09 | 2023-2025 | |
| Seagen INC. | $168.82 | 2022-2023 | Tukysa |
| Janssen Biotech, INC. | $107.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $103.09 | 2021-2025 | Imfinzi, Calquence |
| Karyopharm Therapeutics INC. | $94.27 | 2022-2023 | Xpovio |
| Astellas Pharma US INC | $91.28 | 2020-2023 | Xospata |
| Amgen INC. | $90.19 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $87.84 | 2020-2023 | Eliquis |
| Incyte Corporation | $87.42 | 2020-2022 | |
| Daiichi Sankyo INC. | $79.10 | 2022-2023 | Enhertu |
| Merck Sharp & Dohme LLC | $75.56 | 2021-2025 | Keytruda, Keytruda Qlex |
| Eisai INC. | $72.28 | 2020-2022 | |
| Kerecis Limited | $59.35 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Genzyme Corporation | $58.75 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50.71 | 2022-2023 | Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $44.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.30 | 2019-2024 | |
| Abbvie INC. | $30.86 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $29.11 | 2020 | |
| Janssen Pharmaceuticals, INC | $26.22 | 2022 | |
| Sirtex Medical INC | $20.60 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Galvanize Therapeutics, INC | $15.76 | 2024 | Aliya System |
| Pfizer INC. | $15.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $14.99 | 2021 | |
| W. L. Gore & Associates, INC. | $14.87 | 2019 | |
| Acceleron Pharma, INC. | $14.76 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.47 | 2020 | |
| Tersera Therapeutics LLC | $13.78 | 2022 | |
| Genentech USA, INC. | $13.12 | 2021 | |
| Celgene Corporation | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.